Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified Health Condition 2: K77- Liver disorders in diseases classified elsewhere Health Condition 3: K758- Other specified inflammatory liverdiseases
Conditions
Interventions
None listed
Sponsors
Dayanand Ayurvedic College
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients willing for study or trial. 2.Randomly selected irrespective of their caste, religion and sex. 3.Patients within the age group of 18-65 years. 4.Voluntary agreement & enrollment to participate in the study. 5.Patients who are fit for Basti Karma. 6.The ratio of AST/ALT below 2. 7.Patients having alterations in Liver function tests with and without the symptoms of Kamala. 8.Non-alcoholic Fatty Liver Disease diagnosed by abdomen ultrasonic examination of fatty liver changes grade 1 and grade 2 only.
Exclusion criteria
Exclusion criteria: 1.Patients consuming alcohol. 2.Patients will be excluded from the study if they have chronic diseases such as bronchial asthma, cushing syndrome, malignancies, cerebrovascular accidents, myocardial infarction, chronic kidney disease or any liver dysfunction beyond non-alcoholic fatty liver disease. Additionally, patients with HIV, tuberculosis, other infectious diseases, major psychiatric issues or metabolic syndromes will also be excluded. 3.Prior treatment with any medicine that affects the treatment of Non- Alcoholic Fatty Liver Disease within 3 months. 4.Patient on prolonged more than 6 weeks medication with corticosteroids, antidepressants, anticholinergic, hepato-toxic medicines or any other drug that may influence the outcome of the study. 5.Pregnant and Lactating women will be excluded. 6.The patient has a history of hypersensitivity to the trial drug or any of its ingredients. 7.Drug abusers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Significant improvement in the clinical symptoms of NAFLD: 1.Aruchi (Anorexia) 2.Avipaka (Indigestion) 3.Udarshula (Abdominal pain) 4.Agnimandya (Diminution of the Agni) 5.Utklesha (Nausea) 6.Chardi (Vomiting) Timepoint: Assessment will be done in both the groups: 1.Day 0:At the time of enrollment. 2.Day 20th:At the end of the Basti (for Group A). 3.Day 48th:At the end of the treatment ( for Group A ). 4.Day 45th:At the end of the treatment ( for Group B ). 5.Day 60:At the time of follow up (for both the Groups A and B). | — |
Secondary
| Measure | Time frame |
|---|---|
| Significant Improvement in Objective parameters: 1. Reduction in SGOT. 2. Reduction in SGPT. 3. Reduction in Alkaline Phosphatase. Timepoint: Assessment will be done in both the groups: 1.Day 0:At the time of enrollment. 2.Day 20th:At the end of the Basti (for Group A). 3.Day 48th:At the end of the treatment ( for Group A ). 4.Day 45th:At the end of the treatment ( for Group B ). 5.Day 60th:At the time of follow up (For both the Groups A and B). | — |
Countries
India
Contacts
Public ContactDr Simranjot Kaur
Dayanand Ayrvedic College, Jalandhar
Outcome results
None listed